Probability of Hepatocellular Carcinoma, Serum
Use
The test is used for calculating the risk for patients with chronic liver disease to develop hepatocellular carcinoma (HCC). The GALAD (gender, age, AFP-L3, AFP, des-gamma-carboxy prothrombin) model combines biomarkers and patient demographics to estimate HCC risk. The GALAD score is proven to offer higher diagnostic accuracy for HCC detection compared to AFP, AFP-L3, and DCP markers alone, and has also been shown to outperform ultrasound for HCC detection.
Special Instructions
This test is not orderable individually and must be requested as part of the Hepatocellular Carcinoma Risk Panel with GALAD Score, Serum. The test days are Monday, Wednesday, and Friday, and same day to 1 to 4 days for report availability. The laboratory retains specimens for 3 months after testing.
Limitations
Test results cannot be considered absolute evidence for the presence or absence of malignant disease. Notably, total AFP and AFP-L3 values are not reliable during pregnancy for malignancy investigation. Certain medications, especially those containing vitamin K or its antagonists, can interfere with DCP values. Antibodies to mouse or other animal antibodies present in some individuals may also cause interference in immunoassays, requiring careful result interpretation.
New York Approved
Methodology
Other
Biomarkers
LOINC Codes
- 96709-1
- 96709-1
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.25 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 5 days |
| Frozen | 90 days |